Arbutus Biopharma Corporation ABUS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's total liabilities & equity?
- Arbutus Biopharma Corporation (ABUS) reported total liabilities & equity of $277.16M in Q1 2026.
- How has Arbutus Biopharma Corporation's total liabilities & equity changed year-over-year?
- Arbutus Biopharma Corporation's total liabilities & equity increased by 136.9% year-over-year, from $117.01M to $277.16M.
- What is the long-term trend for Arbutus Biopharma Corporation's total liabilities & equity?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's total liabilities & equity has grown at a -7.1% compound annual growth rate (CAGR), from $137.08M to $94.62M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.